OncoCyte Corp reports results for the quarter ended in June - Earnings Summary

Insight Molecular Diagnostics

10/08/2022 22:03

* OncoCyte Corp  OCX.OQ  reported a quarterly adjusted loss
of 7
cents​​ per share for the quarter ended in June. The mean
expectation of seven analysts for the quarter was for a loss
of 11 cents per share.
    * Revenue rose 1.8% to $2.07 million from a year ago;
analysts
expected $2.70 million. 
    * OncoCyte Corp's reported EPS for the quarter was a loss
of 7
cents​.
    * The mean earnings estimate of analysts had risen by
about 5.8%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * OncoCyte Corp shares had fallen by 4.4% this quarter and
lost 60.4% so far this year.
    * The company reported a quarterly loss of $8.3 million.
    * Wall Street's median 12-month price target for OncoCyte
Corp is
$3.13 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 10
at 09:03 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.11          -0.07          Beat
 Mar. 31 2022      -0.12          -0.11          Beat
 Dec. 31 2021      -0.13          -0.12          Beat
 Sep. 30 2021      -0.12          -0.15          Missed